Immorta

About Immorta

Immorta Bio, a regenerative medicine company, was established in December 2023 by the Venvalo Group. The leadership team includes Chairman and CEO, Dr. Boris Reznik, and President and CSO, Dr. Thomas Ichim. The company is dedicated to developing patient-specific therapeutic solutions for treating diseases associated with aging.

The firm's primary focus is on pioneering personalized stem cell technologies. A key process involves taking a small blood sample from a patient to generate "Amenable Stem Cells" (ASC). These cells are then transformed into "Personalized Regenerative Cells" (PRC) through a proprietary reverse differentiation technology. The resulting PRCs are functionally similar to embryonic stem cells and can be used to create cells for any tissue or organ requiring regeneration. This approach addresses limitations of existing stem cell therapies, such as the rejection of non-patient-specific (allogeneic) cells and the limited numbers or dysfunction of a patient's own adult stem cells. The cells created are patient-specific, "biologically younger," and can be produced in unlimited quantities.

Immorta Bio's technology pipeline features several platforms. The Personalized Progenitor Cell (PPC) platform, for which a patent application has been filed, uses organ-specific molecules and "injury signals" to transform regenerative cells into cells that can directly restore aged or damaged tissues. The company's StemCell Revivify™ aims to rebuild damaged organs and tissues, while the SenoVax™ platform is an autologous approach to eliminate senescent (aging) cells. While the technology has broad potential applications, initial efforts are concentrated on gaining FDA clearance for treating heart failure, liver failure, and multiple organ failure. The company has announced a patent filing for its PMSC-11 stem cell therapy in the successful treatment of a liver failure model. Looking forward, Immorta Bio plans to offer banking of Personalized Regenerative Cells (PRCs) for healthy individuals and patients.